Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Screening and analysis of breast cancer genes regulated by the human mammary microenvironment in a humanized mouse model.

Zheng M, Wang J, Ling L, Xue D, Wang S, Zhao Y.

Oncol Lett. 2016 Dec;12(6):5261-5268. doi: 10.3892/ol.2016.5310. Epub 2016 Oct 24.

2.

NES1/KLK10 gene represses proliferation, enhances apoptosis and down-regulates glucose metabolism of PC3 prostate cancer cells.

Hu J, Lei H, Fei X, Liang S, Xu H, Qin D, Wang Y, Wu Y, Li B.

Sci Rep. 2015 Nov 30;5:17426. doi: 10.1038/srep17426.

3.

Prognostic significance of multiple kallikreins in high-grade astrocytoma.

Drucker KL, Gianinni C, Decker PA, Diamandis EP, Scarisbrick IA.

BMC Cancer. 2015 Aug 1;15:565. doi: 10.1186/s12885-015-1566-5.

4.

Characterization of Changes in Global Genes Expression in the Distal Colon of Loperamide-Induced Constipation SD Rats in Response to the Laxative Effects of Liriope platyphylla.

Kim JE, Park SH, Kwak MH, Go J, Koh EK, Song SH, Sung JE, Lee HS, Hong JT, Hwang DY.

PLoS One. 2015 Jul 7;10(7):e0129664. doi: 10.1371/journal.pone.0129664. eCollection 2015.

5.

Correlation between KLK6 expression and the clinicopathological features of glioma.

Lou J, Si H, Chen Y, Sun X, Zhang H, Niu A, Hu C.

Contemp Oncol (Pozn). 2014;18(4):246-51. doi: 10.5114/wo.2014.44628. Epub 2014 Aug 30.

6.

Chemoprevention activity of dipyridamole in the MMTV-PyMT transgenic mouse model of breast cancer.

Wang C, Schwab LP, Fan M, Seagroves TN, Buolamwini JK.

Cancer Prev Res (Phila). 2013 May;6(5):437-47. doi: 10.1158/1940-6207.CAPR-12-0345. Epub 2013 Feb 27.

7.

HtrA3 Is Downregulated in Cancer Cell Lines and Significantly Reduced in Primary Serous and Granulosa Cell Ovarian Tumors.

Singh H, Li Y, Fuller PJ, Harrison C, Rao J, Stephens AN, Nie G.

J Cancer. 2013;4(2):152-64. doi: 10.7150/jca.5702. Epub 2013 Feb 1.

8.

Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer.

Olkhov-Mitsel E, Van der Kwast T, Kron KJ, Ozcelik H, Briollais L, Massey C, Recker F, Kwiatkowski M, Fleshner NE, Diamandis EP, Zlotta AR, Bapat B.

Epigenetics. 2012 Sep;7(9):1037-45. Epub 2012 Aug 9.

9.

Kallikreins 5, 6 and 10 differentially alter pathophysiology and overall survival in an ovarian cancer xenograft model.

Pépin D, Shao ZQ, Huppé G, Wakefield A, Chu CW, Sharif Z, Vanderhyden BC.

PLoS One. 2011;6(11):e26075. doi: 10.1371/journal.pone.0026075. Epub 2011 Nov 15.

10.

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.

Laffaire J, Everhard S, Idbaih A, Crinière E, Marie Y, de Reyniès A, Schiappa R, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Thillet J, Ducray F.

Neuro Oncol. 2011 Jan;13(1):84-98. doi: 10.1093/neuonc/noq110. Epub 2010 Oct 5.

11.

Smad signaling is required to maintain epigenetic silencing during breast cancer progression.

Papageorgis P, Lambert AW, Ozturk S, Gao F, Pan H, Manne U, Alekseyev YO, Thiagalingam A, Abdolmaleky HM, Lenburg M, Thiagalingam S.

Cancer Res. 2010 Feb 1;70(3):968-78. doi: 10.1158/0008-5472.CAN-09-1872. Epub 2010 Jan 19.

12.

Epigenetic targeting in breast cancer: therapeutic impact and future direction.

Lustberg MB, Ramaswamy B.

Drug News Perspect. 2009 Sep;22(7):369-81. doi: 10.1358/dnp.2009.22.7.1405072. Review.

13.

Functional roles of human kallikrein-related peptidases.

Sotiropoulou G, Pampalakis G, Diamandis EP.

J Biol Chem. 2009 Nov 27;284(48):32989-94. doi: 10.1074/jbc.R109.027946. Epub 2009 Oct 9. Review.

14.

Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.

Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, Hoon DS.

Breast Cancer Res. 2008;10(3):R46. doi: 10.1186/bcr2098. Epub 2008 May 16.

15.

Hypermethylation of the 5' CpG island of the gene encoding the serine protease Testisin promotes its loss in testicular tumorigenesis.

Manton KJ, Douglas ML, Netzel-Arnett S, Fitzpatrick DR, Nicol DL, Boyd AW, Clements JA, Antalis TM.

Br J Cancer. 2005 Feb 28;92(4):760-9. Erratum in: Br J Cancer. 2015 Dec 1;113(11):1640.

16.

Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer.

Tanimoto H, Shigemasa K, Tian X, Gu L, Beard JB, Sawasaki T, O'Brien TJ.

Br J Cancer. 2005 Jan 31;92(2):278-83.

17.

Kallikrein gene downregulation in breast cancer.

Yousef GM, Yacoub GM, Polymeris ME, Popalis C, Soosaipillai A, Diamandis EP.

Br J Cancer. 2004 Jan 12;90(1):167-72.

18.

The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer.

Yousef GM, Scorilas A, Magklara A, Memari N, Ponzone R, Sismondi P, Biglia N, Abd Ellatif M, Diamandis EP.

Br J Cancer. 2002 Nov 18;87(11):1294-300.

19.

Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker.

Hoffman BR, Katsaros D, Scorilas A, Diamandis P, Fracchioli S, Rigault de la Longrais IA, Colgan T, Puopolo M, Giardina G, Massobrio M, Diamandis EP.

Br J Cancer. 2002 Sep 23;87(7):763-71.

20.

Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance.

Luo LY, Diamandis EP, Look MP, Soosaipillai AP, Foekens JA.

Br J Cancer. 2002 Jun 5;86(11):1790-6.

Supplemental Content

Support Center